Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack.
Anxin WangXia MengXue TianS Claiborne JohnstonHao LiPhilip M BathYingting ZuoXuewei XieJing JingJinxi LinYilong WangXing-Quan ZhaoZixiao LiYong JiangLiping LiuFeng WangYing LiJingyao LiuYongjun Wangnull nullPublished in: Annals of neurology (2022)
Bleeding events mostly occurred within the 21-day dual antiplatelet therapy stage and were generally mild. The risk of bleeding was greater in nonsmoking patients, and was associated with treatment with ticagrelor-aspirin compared with clopidogrel-aspirin, particularly in patients aged <65 years and nondiabetic patients. ANN NEUROL 2022;91:380-388.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- ejection fraction
- newly diagnosed
- atrial fibrillation
- prognostic factors
- low dose
- peritoneal dialysis
- type diabetes
- cardiovascular disease
- patient reported outcomes
- coronary artery disease
- oxidative stress
- cardiovascular events
- combination therapy